留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

霉酚酸酯治疗糖尿病肾病的研究进展

杨花,  王妍春

downloadPDF
文章导航 > 分子影像学杂志  > 2016 >  39(2): 180-182
杨花, 王妍春. 霉酚酸酯治疗糖尿病肾病的研究进展[J]. 分子影像学杂志, 2016, 39(2): 180-182. doi: 10.3969/j.issn.1674-4500.2016.02.32
引用本文: 杨花, 王妍春. 霉酚酸酯治疗糖尿病肾病的研究进展[J]. 分子影像学杂志, 2016, 39(2): 180-182. doi: 10.3969/j.issn.1674-4500.2016.02.32
shu
Hua YANG, Yanchun WANG. The progress in research of mycophenolate mofetil in treatment of diabetic kidneydisease[J]. Journal of Molecular Imaging, 2016, 39(2): 180-182. doi: 10.3969/j.issn.1674-4500.2016.02.32
Citation: Hua YANG, Yanchun WANG. The progress in research of mycophenolate mofetil in treatment of diabetic kidney disease[J]. Journal of Molecular Imaging, 2016, 39(2): 180-182. doi: 10.3969/j.issn.1674-4500.2016.02.32
shu

霉酚酸酯治疗糖尿病肾病的研究进展

doi: 10.3969/j.issn.1674-4500.2016.02.32
  • 1.

    广东药科大学，广东 广州 10006

  • 2.

    中国人民解放军广州军区广州总医院，广东 广州 10010

详细信息
    作者简介:

    杨花，E-mail: 15515259275@163.com

    通讯作者:

    王妍春，博士，副主任医师，E-mail: gz623@163.com

The progress in research of mycophenolate mofetil in treatment of diabetic kidney disease

  • 1.

    Guangdong Pharmaceutical University, Guangzhou 510006, China

  • 2.

    Guangzhou General Hospital of Guangzhou Military Command,Guangzhou 510010, China

    摘要
  • 摘要: 糖尿病肾病是糖尿病代谢异常引起的肾脏疾病，是全身微血管病的一部分，也是许多发展中国家终末期肾病的常见病因。近些年来，伴随着各项医疗技术的发展，有效控制了许多疾病，但是糖尿病肾病这种疾病仍旧尚未得到有效治疗，与其相关的发病率和死亡率有逐年上升的趋势。目前，相关研究发现，新型免疫抑制剂霉酚酸酯对糖尿病肾病具有一定的治疗作用。本文就新型免疫抑制剂霉酚酸酯对糖尿病肾病治疗的研究进展作一综述。

     

    Abstract: Diabetic kidney disease(DKD)is a kidney disease caused by metabolic abnormalities, with is a part of systemic microangiopathy, and also the common causes for end stage renal disease(ESRD) in many developing countries. With the develop-ment of medical treatment technique, lots of diseases have been controlled effectively in recent years. However, no effective therapy modes have been created to DKD, which keeps unimproved death rate and increased attack rate year by year.At present, the curative effect of Mycophenolate mofetil(MMF), a new type of immunosuppressant, on DKD has been reported by researchers. This paper reviews the progress in research of MMF in treatment of Diabetic kidney disease.

     

    • HTML全文
    • 参考文献(23)
  • [1] Kaul K, Hodgkinson A, Tarr JM, et al. Is inflammation a common retinal-renal-nerve pathogenic Link in diabetes[J]. Curr Diabetes Rev, 2010, 6(5): 294-303. doi: 10.2174/157339910793360851
    [2] Martini S, Eichinger F, Nair V, et al. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge[J]. Rev Endocr Metab Disord, 2008, 9(4): 267-74. doi: 10.1007/s11154-008-9103-3
    [3] Juan F. Navarro-Gonzalez CM,de fuentes&javier Garcia-Perez MM. inflammatory molecules and pathways in the pathog-enesis of diabetic nephropathy[J]. Nat Rev Nephrol, 2011(7): 327-40. http://cn.bing.com/academic/profile?id=1996854381&encoded=0&v=paper_preview&mkt=zh-cn
    [4] Bellush LL, Doublier S, Holland AN, et al. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice[J]. Endocrinology, 2000, 141(1): 163-8. doi: 10.1210/endo.141.1.7284
    [5] Wu J, Guan TJ, Zheng S, et al. Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice[J]. Lab Invest, 2011, 91(10): 1459-71. doi: 10.1038/labinvest.2011.93
    [6] Navarro JF, Mora C, Maca M, et al. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus [J]. Am J Kidney Dis, 2003, 42(1): 53-61. doi: 10.1016/S0272-6386(03)00408-6
    [7] Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: An update[J]. Drugs Today (Barc), 2009, 45(7): 521-32. http://cn.bing.com/academic/profile?id=2442585748&encoded=0&v=paper_preview&mkt=zh-cn
    [8] Huang HD, Liu ZH, Zhu XJ, et al. Inhibition of mycophenolate acid on NF-KappaB act ivity in human endothelial cells[J]. Acta Pharmaeol Sin, 2002, 23(7): 649-53. http://www.ncbi.nlm.nih.gov/pubmed/12100761
    [9] Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy[J]. Kidney Int, 2010, 77(6): 543-9. doi: 10.1038/ki.2009.499
    [10] F L, Y T, X P, et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis[J]. Lupus, 2008, 17(7): 622-9. doi: 10.1177/0961203308089428
    [11] 刘 东, 伦立德, 郑晓勇. 炎症在 2 型糖尿病患者肾功能损害中的作用[J]. 临床内科杂志, 2005, 22(2): 98-100.
    [12] Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy[J]. Nat Rev Nephrol, 2011, 7(6): 327-40. doi: 10.1038/nrneph.2011.51
    [13] Lee FT, Cao Z, Long DM, et al. Interactions between angiotensin Ⅱ and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy[J]. J Am Soc Nephrol, 2004, 15(8): 2139-51. doi: 10.1097/01.ASN.0000135055.61833.A8
    [14] Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats [J]. J Am Soc Nephrol, 2006, 17(5): 1362-72. doi: 10.1681/ASN.2005111196
    [15] 申鹏霄, 王建生, 赵瑛瑛. 霉酚酸酯对糖尿病肾病大鼠肾组织 TLR4､ IL-18表达的影响[J]. 郑州大学学报:医学版, 2014, 49(6): 808-11. http://cdmd.cnki.com.cn/Article/CDMD-10366-1013337337.htm
    [16] Zhang Y, Chen B, Hou XH, et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats[J]. Chin Med J, 2007, 120(11): 988-95. http://cn.bing.com/academic/profile?id=188514113&encoded=0&v=paper_preview&mkt=zh-cn
    [17] 王明生. 苯那普利联合霉酚酸酯治疗早期糖尿病肾病的疗效观察[J]. 湖南师范大学学报: 医学版, 2006, 3(2): 46-8. http://www.cnki.com.cn/Article/CJFDTOTAL-JLYX201602085.htm
    [18] 余堂宏, 贾汝汉, 丁国华, 等. 霉酚酸酯对 2 型糖尿病大鼠肾脏的保护 作用[J]. 中国临床药理学与治疗学, 2004, 9(10): 1119-22. http://www.cnki.com.cn/Article/CJFDTOTAL-JXSB200605005.htm
    [19] Zhang C, Zhu Z, Wang G, et al. E f fects of mycoph enolate mofetil on renal interst itial f ibros is after unilateral u-reteral obst ru ct ion in rats[J]. J Huazhong Univ Sci Technolog Med Sci, 2003, 23(3): 269-70. doi: 10.1007/BF02829510
    [20] Allison AC. Mechanisms of action of mycophenolate mofetil[J].Lupus, 2005, 14(Suppl 1): s2-8. http://cn.bing.com/academic/profile?id=2074604840&encoded=0&v=paper_preview&mkt=zh-cn
    [21] Luo L, Sun Z, Wu W, et al. Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy[J]. BMC Nephrol, 2012, 13(6): 53-5. http://cn.bing.com/academic/profile?id=1979931202&encoded=0&v=paper_preview&mkt=zh-cn
    [22] Ginzler EM, Dooley M, Aranow C, et al. Mycophenolatemofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353(4): 2219-28. http://cn.bing.com/academic/profile?id=2160388191&encoded=0&v=paper_preview&mkt=zh-cn
    [23] 刘丽红. 霉酚酸酯治疗原发难治性肾病综合征的临床效果[J]. 中国当 代医药, 2014, 21(21): 97-8, 101. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201421042.htm
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  554
  • HTML全文浏览量:  177
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-03-14
  • 刊出日期:  2016-04-01

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日